The effects of safinamide on dysphagia in Parkinson's disease

Dysphagia is a potentially fatal symptom of Parkinson's disease (PD) and is characterized by frequent silent aspiration, a risk factor for aspiration pneumonia. The transdermal dopamine agonist rotigotine alleviates dysphagia in patients with PD and is more effective than oral levodopa, suggest...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2023-05, Vol.18 (5), p.e0286066-e0286066
Main Authors: Hirano, Makito, Samukawa, Makoto, Isono, Chiharu, Nagai, Yoshitaka
Format: Article
Language:English
Subjects:
Alanine
Amine oxidase (flavin-containing)
Analysis
Antiparkinson Agents
Barium
Benzylamines - therapeutic use
Biology and Life Sciences
Care and treatment
Deglutition disorders
Deglutition Disorders - drug therapy
Deglutition Disorders - etiology
Dopa
Dopamine
Dopamine receptors
Drug dosages
Dysphagia
Fluoroscopy
Humans
Inhibitors
Levodopa
Medical research
Medicine and Health Sciences
Medicine, Experimental
Monoamine oxidase
Monoamine Oxidase Inhibitors
Movement disorders
Neurodegenerative diseases
Neurons
Parkinson Disease - complications
Parkinson Disease - drug therapy
Parkinson's disease
Parkinsons disease
Patient outcomes
Pharynx
Physical Sciences
Rasagiline
Retrospective Studies
Risk factors
Social Sciences
Swallowing
Transit time
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dysphagia is a potentially fatal symptom of Parkinson's disease (PD) and is characterized by frequent silent aspiration, a risk factor for aspiration pneumonia. The transdermal dopamine agonist rotigotine alleviates dysphagia in patients with PD and is more effective than oral levodopa, suggesting the importance of continuous dopaminergic stimulation (CDS) in swallowing. Safinamide is a monoamine oxidase B (MAOB) inhibitor that facilitates CDS. In this retrospective open-label evaluator-blinded research, swallowing functions in nine patients with PD were examined using a video fluoroscopic swallowing study (VFSS) before and after treatment with 50 mg of oral safinamide. The VFSS results showed that safinamide significantly improved some swallowing measures during oral and pharyngeal phases, including oral transit time and pharyngeal transit time, without worsening of any measures. Notably, improvements in lip closure, an oral phase component, seemed to be most attributable to improvements in oral phase scores. In conclusion, a medicine for CDS may effectively improve swallowing functions in patients with PD. This is the first study to show that the MAOB inhibitor safinamide partly but significantly improves swallowing function in patients with PD.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0286066